Vaxcyte (PCVX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $65.27, -3.38% vs the prior close of $67.55.
- Volume 2.45M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PCVX slides 3.4% to $65.27. Closed at $65.27, -3.38% vs the prior close of $67.55. Day range $65.00–$68.33, opened at $67.72.
PCVX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PCVX slides 3.4% to $65.27
- Closed at $65.27, -3.38% vs the prior close of $67.55. Day range $65.00–$68.33, opened at $67.72.
- Volume was 2.45M shares, 1.2x its 50-day average of 2.06M.
- Price is +7.0% vs its 50-day average ($60.98) and +16.3% vs its 200-day average ($56.14).
- 52-week range $39.87–$90.75; today's close sits at 50% of that range, 28.1% below the 52-week high.
Oct 14, 2026 — PCVX rises 1.1% to $67.55
- Closed at $67.55, +1.12% vs the prior close of $66.80. Day range $66.00–$69.21, opened at $67.07.
- Volume was 1.53M shares, 0.7x its 50-day average of 2.05M.
- Price is +11.1% vs its 50-day average ($60.80) and +20.5% vs its 200-day average ($56.05).
- 52-week range $39.87–$90.75; today's close sits at 54% of that range, 25.6% below the 52-week high.
Oct 13, 2026 — PCVX slides 5.4% to $66.80
- Closed at $66.80, -5.45% vs the prior close of $70.65. Day range $66.63–$71.09, opened at $70.58.
- Volume was 2.64M shares, 1.3x its 50-day average of 2.01M.
- Price is +10.3% vs its 50-day average ($60.54) and +19.4% vs its 200-day average ($55.94).
- 52-week range $39.87–$90.75; today's close sits at 53% of that range, 26.4% below the 52-week high.
Oct 12, 2026 — PCVX dips 1.0% to $70.65
- Closed at $70.65, -1.02% vs the prior close of $71.38. Day range $68.97–$72.89, opened at $71.08.
- Volume was 2.43M shares, 1.2x its 50-day average of 1.98M.
- Price is +17.2% vs its 50-day average ($60.27) and +26.5% vs its 200-day average ($55.85).
- 52-week range $39.87–$90.75; today's close sits at 60% of that range, 22.1% below the 52-week high.
Oct 9, 2026 — PCVX jumps 9.8% to $71.38 on 2.3x normal volume
- Closed at $71.38, +9.79% vs the prior close of $65.01. Day range $64.78–$72.44, opened at $64.78.
- Volume was 4.38M shares, 2.3x its 50-day average of 1.91M — unusually heavy trading.
- Price is +19.1% vs its 50-day average ($59.94) and +28.1% vs its 200-day average ($55.73).
- 52-week range $39.87–$90.75; today's close sits at 62% of that range, 21.3% below the 52-week high.
- SEC filings that day: 8-K.
Oct 8, 2026 — PCVX dips 2.9% to $65.01 on 2.1x normal volume
- Closed at $65.01, -2.90% vs the prior close of $66.96. Day range $63.79–$67.97, opened at $67.14.
- Volume was 3.85M shares, 2.1x its 50-day average of 1.85M — unusually heavy trading.
- Price is +9.0% vs its 50-day average ($59.63) and +16.9% vs its 200-day average ($55.62).
- 52-week range $39.87–$90.75; today's close sits at 49% of that range, 28.4% below the 52-week high.
- SEC filings that day: 424B5, 424B5.
Oct 7, 2026 — PCVX rises 0.4% to $66.96 on 7.0x normal volume
- Closed at $66.96, +0.39% vs the prior close of $66.70. Day range $64.27–$67.15, opened at $65.86.
- Volume was 11.56M shares, 7.0x its 50-day average of 1.65M — unusually heavy trading.
- Price is +12.7% vs its 50-day average ($59.39) and +20.6% vs its 200-day average ($55.52).
- 52-week range $39.87–$90.75; today's close sits at 53% of that range, 26.2% below the 52-week high.
Oct 6, 2026 — PCVX slides 9.6% to $66.70 on 6.9x normal volume
- Closed at $66.70, -9.65% vs the prior close of $73.82. Day range $63.90–$73.39, opened at $73.35.
- Volume was 10.16M shares, 6.9x its 50-day average of 1.47M — unusually heavy trading.
- Price is +12.8% vs its 50-day average ($59.15) and +20.4% vs its 200-day average ($55.41).
- 52-week range $39.87–$90.75; today's close sits at 53% of that range, 26.5% below the 52-week high.
- SEC filings that day: 424B5, 424B5.
Oct 5, 2026 — PCVX jumps 30.7% to $73.82, a 52-week high on 12.6x normal volume
- Closed at $73.82, +30.70% vs the prior close of $56.48. Day range $71.60–$90.75, opened at $87.21.
- Volume was 14.92M shares, 12.6x its 50-day average of 1.19M — unusually heavy trading.
- Price is +25.3% vs its 50-day average ($58.92) and +33.5% vs its 200-day average ($55.29).
- 52-week range $39.87–$90.75; today's close sits at 67% of that range, 18.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — PCVX rises 0.8% to $56.48 on 2.1x normal volume
- Closed at $56.48, +0.77% vs the prior close of $56.05. Day range $55.84–$57.00, opened at $56.76.
- Volume was 2.40M shares, 2.1x its 50-day average of 1.16M — unusually heavy trading.
- Price is -3.5% vs its 50-day average ($58.54) and +2.4% vs its 200-day average ($55.14).
- 52-week range $37.69–$65.00; today's close sits at 69% of that range, 13.1% below the 52-week high.
PCVX latest news & SEC filings
Every SEC filing by or about PCVX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 8.01 — Reported other events the company considers important.
Oct 8, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 8, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wassil Jim converted options/RSUs into 18,000 shares at $5.35 (≈$96.30K) on Oct 5, 2026; now holds 163,435
- Wassil Jim sold 18,000 shares at $86.74 (≈$1.56M) on Oct 5, 2026; now holds 145,435
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cowan Elvia converted options/RSUs into 19,000 shares at $25.92 (≈$492.48K) on Oct 5, 2026; now holds 46,860
- Cowan Elvia sold 19,000 shares at $86.74 (≈$1.65M) on Oct 5, 2026; now holds 27,860
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wassil Jim converted options/RSUs into 2,250 shares at $5.35 (≈$12.04K) on Oct 1, 2026; now holds 147,685
- Wassil Jim sold 2,155 shares at $56.65 (≈$122.09K) on Oct 1, 2026; now holds 145,530
- Wassil Jim sold 95 shares at $57.09 (≈$5.42K) on Oct 1, 2026; now holds 145,435
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade PCVX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 24, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.24% (largest 30.7%). That is a volatile stock.
- Liquidity: about 3.60M shares (≈$234.67M) trade per day on average.
- 52-week position: $65.27 vs a range of $39.87–$90.75 (50% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jim Wassil sold 1,334 shares on Sep 9, 2026.
- Latest filings: 8-K Oct 9, 2026; 8-K Oct 5, 2026; 8-K Sep 3, 2026.
- Share count: 148.81M shares outstanding (Aug 3, 2026), +14.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
PCVX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 67.72 | 68.33 | 65.00 | 65.27 | 2.45M |
| Oct 14, 2026 | 67.07 | 69.21 | 66.00 | 67.55 | 1.53M |
| Oct 13, 2026 | 70.58 | 71.09 | 66.63 | 66.80 | 2.64M |
| Oct 12, 2026 | 71.08 | 72.89 | 68.97 | 70.65 | 2.43M |
| Oct 9, 2026 | 64.78 | 72.44 | 64.78 | 71.38 | 4.38M |
| Oct 8, 2026 | 67.14 | 67.97 | 63.79 | 65.01 | 3.85M |
| Oct 7, 2026 | 65.86 | 67.15 | 64.27 | 66.96 | 11.56M |
| Oct 6, 2026 | 73.35 | 73.39 | 63.90 | 66.70 | 10.16M |
| Oct 5, 2026 | 87.21 | 90.75 | 71.60 | 73.82 | 14.92M |
| Oct 2, 2026 | 56.76 | 57.00 | 55.84 | 56.48 | 2.40M |
| Oct 1, 2026 | 56.73 | 57.17 | 55.99 | 56.05 | 1.17M |
| Sep 30, 2026 | 56.69 | 57.51 | 56.13 | 56.90 | 1.51M |
| Sep 29, 2026 | 57.96 | 58.98 | 55.91 | 56.69 | 1.49M |
| Sep 28, 2026 | 56.50 | 58.82 | 55.75 | 58.27 | 1.85M |
| Sep 25, 2026 | 57.22 | 57.50 | 55.92 | 56.21 | 947.30K |
| Sep 24, 2026 | 55.86 | 57.59 | 55.08 | 56.90 | 1.85M |
| Sep 23, 2026 | 59.02 | 59.10 | 55.09 | 56.49 | 1.65M |
| Sep 22, 2026 | 59.45 | 59.96 | 58.78 | 59.02 | 1.28M |
| Sep 21, 2026 | 59.00 | 60.53 | 57.62 | 58.92 | 1.12M |
| Sep 18, 2026 | 60.37 | 60.37 | 57.01 | 58.13 | 2.72M |
About Vaxcyte
Vaxcyte (PCVX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN CARLOS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1649094.
PCVX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Olivier Brandicourt | Director | Jun 16, 2026 |
| Anne S Drapeau | Director | Jun 16, 2026 |
| John Furey | Director | Jun 16, 2026 |
| Halley E Gilbert | Director | Jun 16, 2026 |
| Jacks Lee | Director | Jun 16, 2026 |
| Teri Loxam | Director | Jun 16, 2026 |
| Heath Lukatch | Director | Jun 16, 2026 |
| John Markels | Director | Jul 16, 2026 |
| Grant Pickering | CHIEF EXECUTIVE OFFICER | Sep 9, 2026 |
| Carlos V Paya | Director | Jun 16, 2026 |
| Moncef Slaoui | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Elvia Cowan | SVP, Finance & CAO | Sep 9, 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | Sep 9, 2026 |
| Andrew Guggenhime | PRESIDENT AND CFO | Sep 9, 2026 |
| Luis Jodar | Chief Medical Officer | Sep 9, 2026 |
| Grant Pickering | CHIEF EXECUTIVE OFFICER | Sep 9, 2026 |
| Jim Wassil | EVP, Chief Scientific Ofc, COO | Sep 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Jim Wassil | Sale | 1,334 | $59.52 |
| Sep 4, 2026 | Jim Wassil | Sale | 1,381 | $61.16 |
| Sep 1, 2026 | Jim Wassil | Sale | 303 | $61.42 |
| Sep 1, 2026 | Jim Wassil | Sale | 1,537 | $60.89 |
| Sep 1, 2026 | Jim Wassil | Sale | 713 | $61.48 |
| Sep 1, 2026 | Jim Wassil | Sale | 924 | $60.96 |
| Aug 5, 2026 | Harpreet S. Dhaliwal | Sale | 17,000 | $55.00 |
| Aug 3, 2026 | Jim Wassil | Sale | 861 | $53.50 |
| Aug 3, 2026 | Jim Wassil | Sale | 1,389 | $54.09 |
| Aug 3, 2026 | Andrew Guggenhime | Sale | 6,956 | $53.76 |
| Aug 3, 2026 | Andrew Guggenhime | Sale | 3,044 | $54.18 |
| Jul 27, 2026 | Grant Pickering | Sale | 622 | $55.54 |
| Jul 27, 2026 | Grant Pickering | Sale | 244 | $55.96 |
| Jul 27, 2026 | Grant Pickering | Sale | 756 | $55.52 |
| Jul 27, 2026 | Grant Pickering | Sale | 4,415 | $55.93 |
PCVX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-766.63M | -5.63 | $-655.58M |
| Dec 31, 2024 | — | $-463.93M | -3.80 | $-452.63M |
| Dec 31, 2023 | — | $-402.27M | -4.14 | $-296.79M |
| Dec 31, 2022 | — | $-223.49M | -3.44 | $-170.60M |
| Dec 31, 2021 | — | $-100.08M | -1.93 | $-121.39M |
Latest balance sheet: total assets $3.14B, total liabilities $380.21M, cash $183.19M (as of Jun 30, 2026).
PCVX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $55.92 |
| May 6, 2026 | 8-K Item 2.02 (results) | $57.10 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $61.35 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $41.35 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $33.00 |
| May 7, 2025 | 8-K Item 2.02 (results) | $29.00 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $79.35 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $107.56 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PCVX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.